SUPN FY 2023 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

FY 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$608M-8.9% YoY

Gross Profit

$524M86.2% margin

Operating Income

-$5M-0.9% margin

Net Income

$1M0.2% margin

EPS (Diluted)

$0.02

Cash Flow

Operating Cash Flow

$111M

Free Cash Flow

$111M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$356M

Stockholders' Equity

$922M

Cash & Equivalents

$75M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$608M	$667M	-8.9%
Gross Profit	$524M	$580M	-9.7%
Operating Income	-$5M	$46M	-111.4%
Net Income	$1M	$61M	-97.8%